Genelux (GNLX) Revenue & Revenue Breakdown
Genelux Revenue Highlights
Latest Revenue (Y)
$170.00K
Genelux Revenue by Period
Genelux Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | -98.46% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Genelux Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | -100.00% |
2024-03-31 | - | -99.45% |
2023-12-31 | - | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | -100.00% |
2023-03-31 | - | 150.00% |
2022-12-31 | - | -99.38% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Genelux Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AMLX | Amylyx Pharmaceuticals | - | - |
IVA | Inventiva | - | - |
NAMS | NewAmsterdam Pharma Company | - | - |
IKNA | Ikena Oncology | - | - |
CNTA | Centessa Pharmaceuticals | - | - |
DYAI | Dyadic | - | - |
GNLX | Genelux | - | - |
CGEM | Cullinan Oncology | - | - |
IMRX | Immuneering | - | - |
DAWN | Day One Biopharmaceuticals | - | - |
CING | Cingulate | - | - |
ABOS | Acumen Pharmaceuticals | - | - |
TERN | Terns Pharmaceuticals | - | - |
CELC | Celcuity | - | - |
LRMR | Larimar Therapeutics | - | - |
MNPR | Monopar Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | - |
CMPX | Compass Therapeutics | - | - |
MLTX | MoonLake Immunotherapeutics | - | - |